(VIANEWS) – Shares of TherapeuticsMD (NASDAQ: TXMD) fell 9.47% to $3.95 at 12:29 EST on Friday, after two sequential sessions in a row of losses. NASDAQ is dropping 0.73% to $11,255.12, following the last session’s downward trend. This seems, at the moment, a somewhat negative trend trading session today.
TherapeuticsMD’s last close was $4.36, 81.04% below its 52-week high of $23.00.
About TherapeuticsMD
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Earnings Per Share
As for profitability, TherapeuticsMD has a trailing twelve months EPS of $-0.666.
Volatility
TherapeuticsMD’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.37%, a negative 0.44%, and a positive 3.03%.
TherapeuticsMD’s highest amplitude of average volatility was 3.13% (last week), 1.52% (last month), and 3.03% (last quarter).
Sales Growth
TherapeuticsMD’s sales growth is 27.4% for the ongoing quarter and 62.9% for the next.
Revenue Growth
Year-on-year quarterly revenue growth declined by 17.7%, now sitting on 87.49M for the twelve trailing months.
More news about TherapeuticsMD (TXMD).
